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a b s t r a c t 
TDP-43 and FUS are linked to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration
(FTLD), and loss of function of either protein contributes to these neurodegenerative conditions. To
elucidate the TDP-43- and FUS-regulated pathophysiological RNA metabolism cascades, we assessed the
differential gene expression and alternative splicing proﬁles related to regulation by either TDP-43 or
FUS in primary cortical neurons. These proﬁles overlapped by > 25% with respect to gene expression
and > 9% with respect to alternative splicing. The shared downstream RNA targets of TDP-43 and FUS
may form a common pathway in the neurodegenerative processes of ALS / FTLD. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. All rights reserved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disor-
der characterized by the death of motor neurons in the spinal cord,
brainstem, and motor cortex [ 1 ]. Frontotemporal lobar degeneration
(FTLD) is a dementia syndrome characterized by progressive changes
in behavior, personality, and / or language resulting from the grad-
ual deterioration of the frontal and temporal lobes [ 2 , 3 ]. Transactive
response (TAR) DNA-binding protein 43 (TDP-43) and fused in sar-
coma (FUS) have been genetically and pathologically linked to ALS
and FTLD; however, the underlying mechanisms by which TDP-43
and FUS induce ALS and FTLD pathologies are unknown [ 2 , 3 ].  This is an open-access article distributed under the terms of the Creative Com- 
mons Attribution-NonCommercial-No Derivative Works License, which permits non- 
commercial use, distribution, and reproduction in any medium, provided the original 
author and source are credited. 
Abbreviations: ALS, amyotrophic lateral sclerosis; Cugbp1, CUG triplet repeat, RNA- 
binding protein 1; DAVID, Database for Annotation, Visualization and Integrated 
Discovery; FTLD, frontotemporal lobar degeneration; FUS, fused in sarcoma; GFAP, 
glial ﬁbrillary acidic protein; GO, Gene Ontology; hnRNAPs, heterogeneous ribonu- 
cleoproteins; LTP, long-term potentiation; RIN, RNA integrity numbers; RMA, robust 
multichip average; RRMs, RNA recognition motifs; SBMA, spinal and bulbar muscu- 
lar atrophy; shCont, shRNA / control; shCugbp1, shRNA / Cugbp1; shFUS, shRNA / FUS; 
shTDP, shRNA / TDP-43; TDP-43, transactive response (TAR) DNA-binding protein 43; 
TGF, transforming growth factor. 
* Corresponding authors. Address: Department of Neurology, Nagoya University 
Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan. Tel.: 
+ 81 52 744 2391; fax: + 81 52 744 2785. Tel.: + 81 52 744 2385; fax: + 81 52 744 2785. 
E-mail addresses: ishigaki-ns@umin.net (S. Ishigaki) sobueg@med.nagoya-u.ac.jp 
(G. Sobue). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2211-5463/ $ 36.00 c © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation o
http://dx.doi.org/10.1016/j.fob.2013.11.001 TDP-43 was identiﬁed as a major component of cytoplasmic neu-
ronal inclusions in sporadic ALS and FTLD patients [ 4 , 5 ], and missense
mutations in TARDBP , the gene encoding TDP-43, are a known cause
of familial ALS and FTLD [ 6 –8 ]. Familial cases of ALS and FTLD involv-
ing TDP-43 mutations and sporadic cases of these diseases exhibit
highly similar clinical and pathological characteristics [ 9 ], suggest-
ing that TDP-43 plays an important role in the pathogenesis of spo-
radic ALS and FTLD. Similarly, FUS is also a causative gene for familial
ALS and FTLD; in these diseases, redistribution to the cytoplasm and
the formation of cytoplasmic aggregates occur for both the TDP-43
and FUS proteins [ 10 , 11 ]. TDP-43 and FUS also share many common
pathophysiological characteristics. In particular, these proteins are
structurally similar heterogeneous ribonucleoproteins (hnRNPs), as
both TDP-43 and FUS are RNA-binding proteins with RNA recognition
motifs (RRMs); they are typically predominantly found in the nu-
cleus; their pathological forms are located mainly in the cytosol; and
they are involved in transcription, alternative splicing, translation,
and RNA transport [ 12 –14 ]. 
Although it remains unclear whether a loss of function or gain
of toxicity of TDP-43 or FUS is a major cause of ALS / FTLD, the loss of
these RNA-binding proteins in the nucleus is a plausible trigger of neu-
rodegeneration. This hypothesis has been supported by several lines
of evidence, including the fact that TDP-43 or FUS nuclear staining is
lost in the nuclei of neurons in both human ALS / FTLD tissue [ 15 , 16 ]
and TDP-43 overexpressing mice [ 17 , 18 ]. In addition, animal models
involving the loss of either TDP-43 or FUS mimic the pathology of ALS /
FTLD [ 19 –22 ]. Recently, analyses of TDP-43 using ﬂy models revealedf European Biochemical Societies. All rights reserved. 
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phat the up- and down-regulation of TDP-43 produced highly simi- 
ar transcriptome alterations [ 23 ]. Cross-rescue analysis in Drosophila 
emonstrated that FUS acted together with and downstream of TDP- 
3 in a common genetic pathway [ 21 ]. Thus, it is intriguing to compare
he transcriptome proﬁles from neurons with silenced TDP-43 or FUS. 
his experiment could clarify the common molecular mechanisms of 
LS / FTLD that are associated with TDP-43 and FUS. 
Recently, we investigated the transcriptome proﬁles of FUS reg- 
lation in different cell lineages of the central nervous system and 
etermined that FUS regulates both gene expression and alterna- 
ive splicing events in a cell-speciﬁc manner that is associated with 
LS / FTLD [ 24 ]. In the current study, we investigated the transcrip- 
ome proﬁles of TDP-43-silenced primary cortical neurons and com- 
ared these proﬁles with the transcriptome proﬁles of FUS-silenced 
eurons. The gene expression and alternative splicing event proﬁles 
elated to regulation by TDP-43 and by FUS were rather similar, sug- 
esting that TDP-43 and FUS may regulate common downstream RNA 
argets and molecular cascades that could potentially be associated 
ith the pathomechanisms of ALS / FTLD. 
. Methods 
.1. Lentivirus 
We designed two different shRNAs against mouse Tardbp 
 Tdp-43 ), Fus , and a control shRNA. The targeted sequences were 
 
′ -CGATGAACCCATTGAAATA-3 ′ for shRNA / TDP-43–1 (shTDP1); 
 
′ -GAGTGGAGGTTATGGTCAA-3 ′ for shRNA / TDP-43–2 (shTDP2); 
 
′ -GCAACAAAGCTACGGACAA-3 ′ for shRNA / FUS1 (shFUS1); 5 ′ - 
AGTGGAGGTTATGGTCAA-3 ′ for shRNA / FUS2 (shFUS2); 5 ′ - 
GCTTAAAGTGCAGCTCAA-3 ′ for shRNA / Cugbp1 (shCugbp1); and 
 
′ -AAGCAAAGATGTCTGAATA-3 ′ for shRNA / control (shCont). The 
hRNAs were cloned into a lentiviral shRNA vector (pLenti-RNAi-X2 
uro DEST, w16–1, which was a kind gift from Dr. Eric Campeau at 
esverlogix Corp.). Lentivirus was prepared in accordance with the 
rotocols detailed by Campeau et al. [ 25 ]. 
.2. Primary cortical neuron culture and the depletion of TDP-43 and 
US 
Primary cortical neurons were obtained from the fetal brains 
f C57BL / 6 mouse embryos on embryonic day 15 (E15). The de- 
ailed procedure for acquiring these neurons was described in pre- 
iously published reports [ 26 ]. On day 5, neurons were infected with 
 × 10 10 copies / well (1.5 × 10 7 copies / μl) of lentivirus express- 
ng shRNA against mouse Tdp-43 (shTDP1 or shTDP2), mouse Cugbp1 
CUG triplet repeat, RNA-binding protein 1) (shCugbp1), or scram- 
led control (shCont). The virus-containing media was removed at 
 h after infection. The neurons were then cultured for 6 additional 
ays and harvested on day 11 for RNA extraction and cDNA synthe- 
is. Each knockdown experiment was performed in triplicate for each 
icroarray analysis. Experiments were performed in accordance with 
he Guide for the Care and Use of Laboratory Animals issued by the 
ational Institutes of Health and with the approval of the Nagoya 
niversity Animal Experiment Committee (Nagoya, Japan). The ex- 
eriments on FUS-silenced primary cortical neurons were performed 
n the manner described above and have been detailed in a previously 
ublished report [ 26 ]. 
For immunohistochemical analyses, we used an anti- β-tubulin 
ntibody (TU20, Santa Cruz, Santa Cruz, CA), an anti-glial ﬁbrillary 
cidic protein (GFAP) antibody (EB4, Enzo Life Sciences, Plymouth 
eeting, PA), and 4 ′ ,6-diamidino-2-phenylindole (DAPI) staining. 
For immunoblot analyses, cells were lysed in TNE buffer containing 
rotease inhibitors for 15 min on ice. The lysates were then cleared by centrifuging the cells at 13,000 g for 15 min at 4 ◦C. Lysates were nor- 
malized for total protein (10 μg per lane), separated using a 4–20% lin- 
ear gradient SDS–PAGE and electroblotted. For immunoblot, we used 
anti-FUS antibodies (A300–293A, Bethyl Laboratories, Montgomery, 
TX), anti-TDP-43 antibody (Proteintech, Chicago, IL), and anti-actin 
antibody (Sigma, St. Louis, MO). 
2.3. Microarray analysis 
Total RNA was extracted from primary cortical neurons using 
the RNeasy Mini Kit (Qiagen, Hilden, Germany). We conﬁrmed that 
the RNA integrity numbers (RIN) for the extracted samples were all 
greater than 7.0. We synthesized and labeled cDNA fragments from 
100 ng of total RNA using the GeneChip WT cDNA Synthesis Kit 
(Ambion, Austin, TX). Hybridization and signal acquisition for the 
GeneChip Mouse Exon 1.0 ST Array (Affymetrix, Santa Clara, CA) 
were performed according to the manufacturer’s instructions. Each 
array experiment was performed in triplicate. The robust multichip 
average (RMA) and iterative probe logarithmic intensity error (iter- 
PLIER) methods were employed to normalize exon-level and gene- 
level signal intensities, respectively, using Expression Console 1.1.2 
(Affymetrix). We utilized the gene annotation provided by Ensembl 
version e!61, which is based on the National Center for Biotechnology 
Information (NCBI) Build 37.1 / mm9 of the mouse genome assembly. 
All microarray data were registered in the Gene Expression Omnibus 
with accession numbers of GSE36153 (shFUS) and GSE46148 (shTDP- 
43 and shCugbp1). 
Using Student’s t -test, we compared the gene-level signal intensi- 
ties from three controls treated with shCont with the gene-level sig- 
nal intensities of three samples treated with either shTDP1 or shTDP2. 
We also analyzed alternative splicing proﬁles by ﬁltering the exon- 
level signal intensities, using a t -test with a threshold of p -value ≤0.1. 
Gene expression and alternative splicing proﬁles related to FUS reg- 
ulation in primary cortical neurons were also obtained by compar- 
ing gene-level and exon-level signal intensities from three controls 
treated with shCont with the corresponding signal intensities from 
three samples treated with either shFUS1 or shFUS2, as previously 
described [ 26 ]. As a control for the RNA-binding protein-silencing 
model, we analyzed the gene-level and exon-level signal intensities 
of three samples treated with wither shCugbp1or shCont. 
2.4. RT-PCR for alternative splicing analyses 
Total RNA was isolated from cells using the RNeasy Mini Kit 
(Qiagen). The extracted RNA was then treated with DNase I (Qi- 
agen). cDNA was synthesized from 1 μg of total RNA using 
oligo(dT) primers (Promega, Madison, WI). Primers for each candi- 
date exon were designed using the Primer3 software program ( http: / 
/ frodo.wi.mit.edu / primer3 / input.htm ). The primer sequences are 
provided in Supplementary Table 1 . Semi-quantitative reverse tran- 
scription polymerase chain reaction (RT-PCR) was performed using 
Ex Taq (Takara Bio Inc., Otsu, Japan), with the following ampliﬁca- 
tion conditions: 25–30 cycles of 98 ◦C for 10 s, 60 ◦C for 30 s, and 
72 ◦C for 1 min. The PCR products were electrophoresed on a 15% 
acrylamide gel and stained with ethidium bromide. The intensity of 
each band was measured using the Multi Gauge software program 
(Fujiﬁlm, Tokyo, Japan). 
2.5. Real-time qPCR for gene expression analysis 
The RNeasy Mini Kit (Qiagen) was used to isolate total RNA from 
cells; 1 μg of total RNA was then reverse transcribed, using oligo- 
dT primers. This transcription utilized the CFX96 system (BioRad, 
Hercules, CA) and thermocycler conditions of 95 ◦C for 3 min followed 
by 40 cycles of 95 ◦C for 10 s and 55 ◦C for 30 s. 
Daiyu Honda et al. / FEBS Open Bio 4 (2014) 1–10 3 
Fig. 1. Comparisons of the gene expression and exon splicing proﬁles of TDP-43-silenced primary cortical neurons and FUS-silenced primary cortical neurons. (A) Gene expression 
and alternative splicing proﬁles of TDP-43-silenced primary cortical neurons- and FUS-silenced primary cortical neurons were compared. Venn diagrams indicate the overlaps in 
the genes (top) and exons (bottom) with expression levels that were uniquely or concordantly regulated by TDP-43 and / or FUS ( t -test, p < 0.05; fold change ≤0.67 or ≥1.5). (B) 
The fold changes in overlapping genes ﬁltered by t -tests (with a threshold of p < 0.1) were plotted for TDP-43-silenced primary cortical neurons and FUS-silenced primary cortical 
neurons. Scatter plots of the fold changes in gene expression levels (left) and alternative splicing events (right) for shTDP-43 and shFUS. The R 2 value was calculated for genes and 
exons with t -test p -values < 0.1. 
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Fig. 2. The validation of differentially expressed genes regulated by both TDP-43 and FUS. Twelve genes with differential expression in both TDP-43-silenced neurons and FUS- 
silenced neurons in Table 2 were validated by real-time qPCR ( n = 3; mean and SD). Quantities are calculated by the ratio to β-actin and shown as the relative expression ratio to 
shCont. Five commonly down-regulated genes (A) and seven commonly up-regulated genes (B) are indicated. Statistics were done by one-way ANOVA and Tukey test. * ( p < 0.05), 
** ( p < 0.01), and *** ( p < 0.001) denote signiﬁcant differences. 
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Fig. 3. The validation of representative altered splicing events in TDP-43-silenced primary cortical neurons and FUS-silenced primary cortical neurons. Eight exons with differential 
expression in both TDP-43-silenced neurons and FUS-silenced neurons were validated by semiquantitative RT-PCR. The top panel provides a schematic of splicing changes mediated 
by TDP-43 and / or FUS. The second and third panels display representative RT-PCR results for the indicated exons and the densitometric quantiﬁcation (ratio of inclusion to exclusion) 
of these results ( n = 3; mean and SD) after either TDP-43 or FUS depletion. * p < 0.05 by t -test. Statistics were done by one-way ANOVA and Tukey test. * ( p < 0.05), ** ( p < 0.01), 
and *** ( p < 0.001) denote signiﬁcant differences. 
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Table 1 
Gene Ontology terms for gene expression / alternative splicing in TDP-43- or FUS-silenced neurons. 
shTDP-43 Gene expression shFUS Gene expression 
GO ID Term p -Value GO ID Term p -Value 
GO:0007264 Small GTPase mediated signal 
transduction 
8.37E −07 GO:0019637 Organophosphate metabolic 
process 
3.68E −04 
GO:0007242 Intracellular signaling cascade 1.04E −05 GO:0006644 Phospholipid metabolic process 4.89E −04 
GO:0044271 Nitrogen compound biosynthetic 
process 
2.98E −04 GO:0016055 Wnt receptor signaling pathway 5.21E −04 
GO:0006790 Sulfur metabolic process 9.94E −04 GO:0009100 Glycoprotein metabolic process 5.30E −04 
GO:0009100 Glycoprotein metabolic process 0.00169596 GO:0007264 Small GTPase mediated signal 
transduction 
5.91E −04 
GO:0009101 Glycoprotein biosynthetic process 0.0019038 GO:0006650 Glycerophospholipid metabolic 
process 
8.42E −04 
GO:0018130 Heterocycle biosynthetic process 0.0033067 GO:0007242 Intracellular signaling cascade 0.00122745 
GO:0022604 Regulation of cell morphogenesis 0.00426464 GO:0007265 Ras protein signal transduction 0.00389788 
GO:0016055 Wnt receptor signaling pathway 0.00455985 GO:0046486 Glycerolipid metabolic process 0.00481341 
GO:0031344 Regulation of cell projection 
organization 
0.00619132 GO:0006665 Sphingolipid metabolic process 0.00514754 
GO:0043085 Positive regulation of catalytic 
activity 
0.0063261 GO:0030384 Phosphoinositide metabolic 
process 
0.00562443 
GO:0031345 Negative regulation of cell 
projection organization 
0.00656187 GO:0006793 Phosphorus metabolic process 0.00563812 
GO:0043413 Biopolymer glycosylation 0.00855583 GO:0006796 Phosphate metabolic process 0.00563812 
GO:0006486 Protein amino acid glycosylation 0.00855583 GO:0006643 Membrane lipid metabolic 
process 
0.00613362 
GO:0070085 Glycosylation 0.00855583 GO:0009101 Glycoprotein biosynthetic process 0.00691847 
GO:0010975 Regulation of neuron projection 
development 
0.00912726 GO:0051348 Negative regulation of transferase 
activity 
0.00924863 
GO:0030384 Phosphoinositide metabolic 
process 
0.010632 GO:0006600 Creatine metabolic process 0.01095567 
GO:0010769 Regulation of cell morphogenesis 
involved in differentiation 
0.01225994 GO:0044242 Cellular lipid catabolic process 0.01200742 
GO:0019932 Second-messenger-mediated 
signaling 
0.01617062 GO:0006486 Protein amino acid glycosylation 0.01276803 
GO:0050770 Regulation of axonogenesis 0.01657312 GO:0070085 Glycosylation 0.01276803 
shTDP-43 Alternative splicing shFUS Alternative splicing 
GO ID Term p -Value GO ID Term p -Value 
GO:0016192 Vesicle-mediated transport 2.76E −05 GO:0045202 Synapse 6.85E −07 
GO:0044057 Regulation of system process 2.41E −04 GO:0042995 Cell projection 2.54E −06 
GO:0006936 Muscle contraction 5.09E −04 GO:0043005 Neuron projection 2.29E −05 
GO:0003012 Muscle system process 7.75E −04 GO:0005856 Cytoskeleton 1.73E −04 
GO:0006897 Endocytosis 0.00107681 GO:0005886 Plasma membrane 1.88E −04 
GO:0010324 Membrane invagination 0.00107681 GO:0043232 Intracellular 
non-membrane-bounded 
organelle 
2.07E −04 
GO:0046903 Secretion 0.00244805 GO:0043228 Non-membrane-bounded 
organelle 
2.07E −04 
GO:0048167 Regulation of synaptic plasticity 0.00322575 GO:0044456 Synapse part 3.76E −04 
GO:0050804 Regulation of synaptic 
transmission 
0.00339707 GO:0030424 Axon 5.70E −04 
GO:0050808 Synapse organization 0.00342093 GO:0031252 Cell leading edge 7.01E −04 
GO:0043524 Negative regulation of neuron 
apoptosis 
0.0036232 GO:0044463 Cell projection part 7.08E −04 
GO:0051969 Regulation of transmission of 
nerve impulse 
0.00432752 GO:0030054 Cell junction 7.20E −04 
GO:0006887 Exocytosis 0.00477415 GO:0015630 Microtubule cytoskeleton 0.00738251 
GO:0031644 Regulation of neurological system 
process 
0.00525083 GO:0045211 Postsynaptic membrane 0.00825557 
GO:0032940 Secretion by cell 0.00587779 GO:0042734 Presynaptic membrane 0.0133955 
GO:0006816 Calcium ion transport 0.00667547 GO:0044430 Cytoskeletal part 0.02340953 
GO:0016044 Membrane organization 0.0067241 GO:0044459 Plasma membrane part 0.02454379 
GO:0046777 Protein amino acid 
autophosphorylation 
0.00788146 GO:0001726 Rufﬂe 0.03547283 
GO:0007628 Adult walking behavior 0.01199082 GO:0032589 Neuron projection membrane 0.04340658 
GO:0043523 Regulation of neuron apoptosis 0.01330492 GO:0005938 Cell cortex 0.04544057 
i
o
β
e
aThe relative quantity of each transcript was calculated by creat- 
ng a standard curve using the cycle thresholds for serial dilutions 
f complementary DNA (cDNA) samples, normalized to quantities of 
-actin. The PCR was performed in triplicate for each sample, and all 
xperiments were repeated twice. iQ SYBR Green Supermix (BioRad) 
nd the sets of primers listed in Supplementary Table 1 were used for real-time quantitative polymerase chain reaction (qPCR) ampliﬁ- 
cations. 
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Table 2 
Differentially expressed genes regulated by both TDP-43 and FUS. 
Gene symbol Gene name shTDP FC shFUS FC 
Tgfbr1 Transforming growth factor, beta 
receptor 1 
0.38 0.40 
Tap1 Transporter 1, ATP-binding cassette, 
sub-family B (MDR / TAP) 
0.53 0.41 
Ccbe1 Collagen and calcium binding EGF 
domains 1 
0.60 0.60 
Sla src-like adaptor 0.61 0.58 
Vamp1 Vesicle-associated membrane protein 1 0.66 0.64 
Rab15 RAB15, member RAS oncogene family 1.96 2.10 
Taf9b TAF9B RNA polymerase II, TATA box 
binding protein (TBP)-associated factor 
2.00 3.13 
Ilk Integrin-linked kinase 2.08 2.16 
Nacc1 Nucleus accumbens associated 1, BEN 
and BTB (POZ) domain containing 
2.29 2.49 
Qpctl Glutaminyl-peptide 
cyclotransferase-like 
2.37 2.63 
Syt17 Synaptotagmin 17 3.08 1.82 
Stx1a Syntaxin 1A 3.08 2.45 
Table 3 
Genes with altered exon splicing regulated by both TDP-43 and FUS. 
Gene symbol Gene name Spliced site 
Braf Braf transforming gene Exon12 Skipping 
Camk2a Calcium / calmodulin-dependent 
protein kinase II alpha 
Exon14 Skipping 
Cttn Cortactin Exon11 Skipping 
Deaf1 Deformed epidermal autoregulatory 
factor 1 
Exon2 Skipping 
Erc2 ELKS / RAB6-interacting / CAST family 
member 2 
Exon12 Skipping 
Kcnip1 Kv channel-interacting protein 1 Exon2 Skipping 
Ncor1 Nuclear receptor corepressor 1 Exon9 Skipping 
Anks1b Ankyrin repeat and sterile alpha motif 
domain containing 1B 
Exon7 Inclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3. Results 
3.1. The shRNA-mediated silencing of TDP-43 and FUS in primary 
cortical neurons using lentivirus 
To compare the global proﬁles of RNA molecules regulated by
TDP-43 and FUS in primary cortical neurons, we produced TDP-43-
silenced primary motor neurons by infecting neurons with lentivirus
expressing shRNA against TDP-43; control neurons were produced by
infection with lentivirus expressing RNA against a scrambled control.
The proﬁles of FUS-silenced primary cortical neurons using shFUS1
and shFUS2 were established in a previous study [ 26 ]. The purity of the
primary cortical neurons was conﬁrmed through immunostaining.
We successfully established the desired primary cortical neurons with
a purity of greater than 95% ( Supplementary Fig. S1A ). 
The expression levels of TDP-43 were suppressed by approxi-
mately 60–90% by shTDP1 or shTDP2, as measured by real-time qPCR
( Supplementary Fig. S1B ). The expression levels of FUS were also sup-
pressed by 80–90% by shFUS1 or shFUS2, as reported previously [ 26 ].
The protein levels of TDP-43 were markedly lower in primary neu-
rons infected with shTDP1 and shTDP2 than in neurons infected with
the shCont based on the immunoblot analysis ( Supplementary Fig.
S1C , left). In addition, a reduction in FUS protein levels was observed
in primary neurons infected with shFUS1 or shFUS2 ( Supplementary
Fig. S1C , right). 
As a control for the RNA-binding protein-silencing model, we
knocked down the Cugbp1 gene in primary cortical neurons and con-
ﬁrmed that this knockdown produced a silencing efﬁciency of greater
than 70% ( Supplementary Fig. S2 ).  3.2. Signiﬁcant overlap in the transcriptomes of TDP-43-silenced 
neurons and FUS-silenced neurons 
We analyzed gene expression levels and alternative splicing in
TDP-43-silenced primary neurons using the Affymetrix GeneChip
Mouse Exon 1.0 ST Array (GEO Accession No. GSE46148 ). We used
Student’s t -test to compare the gene-level signal intensities of three
controls treated with shCont with the gene-level signal intensities
of three samples treated with either shTDP1 or shTDP2. Among the
21,603 genes on the mouse exon array, 1411 genes had p -values ≤0.01
for both shTDP1 and shTDP2 treatments in the t -tests, and the corre-
lation coefﬁcient between the fold changes of the shTDP1 and shTDP2
treatments was 0.83 ( Supplementary Fig. S3A ). 
We also analyzed alternative splicing proﬁles by ﬁltering the exon-
level signal intensities using a threshold of a t -test p -value ≤0.1. This
ﬁltering yielded 4973 exons that were altered by both shTDP1 and
shTDP2, with a correlation coefﬁcient of 0.801 ( Supplementary Fig.
S3B ). To identify common effects produced by silencing TDP-43 and
silencing FUS, we compiled a list of differentially expressed genes
and alternatively spliced exons in primary cortical neurons silenced
by shTDP-43 and in primary cortical neurons silenced by shFUS. By
applying the threshold of a t -test p -value of ≤0.05 and a fold change
of ≤0.67 or ≥1.5 for both shTDP1 and shTDP2, we obtained 204 genes
with altered expression levels upon TDP-43 knockdown. Similarly,
183 genes were obtained for FUS by applying the threshold of a t -
test p -value of ≤0.05 and a fold change value of ≤0.67 or ≥1.5 for both
shFUS-1 and shFUS-2. Venn diagrams indicated that the set of genes
or exons with expression that were differentially and consistently
regulated by FUS markedly overlapped with the corresponding set of
genes or exons for TDP-43 ( t -test, p < 0.05). In particular, an overlap
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gf more than 25% was observed among the gene expression proﬁles 
f shTDP-43- and shFUS-treated neurons ( Fig. 1 A, top panel; 51 / 204 
25.0%) of the genes for shTDP-43; 51 / 183 (27.9%) of the genes for 
hFUS). 
We also ﬁltered the exon-level signal intensities by applying a 
hreshold of a t -test p -value of ≤0.05 and a fold change value of ≤0.67 
r ≥1.5. We then determined TDP-43- and FUS-regulated exons as 
ell as the overlap between these exons using the same approach that 
e applied for gene expression. We obtained 675 TDP-43-regulated 
enes and 429 FUS-regulated genes with altered exon expression. 
enn diagrams indicate that there was an overlap of approximately 
0% between the alternative splicing proﬁles produced by shFUS and 
he alternative splicing proﬁles produced by shTDP-43 ( Fig. 1 A, bot- 
om panel; 61 / 674 (9.1%) of the genes for shTDP-43; 61 / 428 (14.3%) 
f the genes for shFUS). 
We then compared the changes in the overlapping genes or exons 
ffected by both shTDP-43 and shFUS after ﬁltering these genes and 
xons using a t -test (with a threshold of p < 0.1). The fold change plot 
nalysis demonstrated a strong correlation between shTDP-43 and 
hFUS with respect to gene expression ( Fig. 1 B left; R 2 = 0.78); in con- 
rast, the gene expression proﬁle for neurons transduced with shRNA 
argeting a different RNA-binding protein, Cugbp1, did not correlate 
ell with the expression proﬁles of neurons transduced with shTDP- 
3 ( R 2 = 0.46) or shFUS ( R 2 = 0.53) ( Supplementary Fig. S4A ). The fold
hange plot analysis of exon splicing also demonstrated a moderate 
orrelation between shTDP-43 and shFUS ( Fig. 1 B right; R 2 = 0.64). 
he exon splicing proﬁle for neurons silenced with shRNA against 
ugbp1 showed lesser correlation with the exon splicing proﬁles of 
eurons transduced with shTDP-43 ( R 2 = 0.52) or shFUS ( R 2 = 0.48) 
 Supplementary Fig. S4B ). 
We next analyzed the Gene Ontology (GO) terms for the genes 
hat were regulated by TDP-43 and FUS ( t -test, p < 0.1; fold change 
f ≤0.77 or ≥1.3) using the Database for Annotation, Visualization 
nd Integrated Discovery (DAVID), version 6.7 [ 27 , 28 ]. Genes regu- 
ated by TDP-43 were mainly categorized as being involved in sig- 
aling cascades and metabolic processes, and the GO terms for these 
enes were similar to the GO terms for genes regulated by FUS. In 
he list of the top 20 GO terms for genes with TDP-43-regulated ex- 
ression and the corresponding list for genes with FUS-regulated ex- 
ression, we identiﬁed eight common GO terms, including “small 
TPase-mediated signal transduction” and “Wnt receptor signaling 
athway” ( Table 1 ). We also compiled the list of top 20 GO terms for 
enes with Cugbp1-regulated expression ( Supplementary Table S2 ). 
nly one and three common GO terms were identiﬁed in between the 
ists of Cugbp1- and TDP-43-regulated expression (GO:0007264) and 
ugbp1- and FUS-regulated expression (GO:0007264, 0019637, and 
006644), respectively. In contrast, the GO terms for genes with TDP- 
3- or FUS-related alternative splicing regulation mainly referred to 
arious neuronal functions; however, none of the same GO terms 
ppeared in both the list of the top 20 GO terms for genes with TDP- 
3-regulated alternative splicing and the corresponding list for genes 
ith FUS-regulated alternative splicing ( Table 1 ). 
.3. Gene expression proﬁles are similar among the top 20 genes 
egulated by TDP-43 and FUS 
We next investigated the detailed gene expression proﬁles of TDP- 
3-silenced primary cortical neurons. By ﬁltering gene-level signal 
ntensities using a t -test (with a threshold of p -value ≤0.1) and fold 
hange (which was required to be ≤0.67 or ≥1.5), genes with differen- 
ial expression in TDP-43-silenced primary cortical neurons were se- 
ected. Fourteen of the top 20 genes with expression regulated by TDP- 
3 were also regulated by FUS ( Supplementary Table S3 ). To select 
enes with differential expression upon changes in FUS regulation, 
ene-level signal intensities in the proﬁle of FUS-silenced primary cortical neurons were ﬁltered using a t -test (with a threshold of p - 
value ≤0.1) and fold change (which was required to be ≤0.67 or ≥1.5). 
Genes that were differentially expressed in both TDP-43-silenced pri- 
mary cortical neurons and FUS-silenced primary cortical neurons (as 
determined by the p -value ≤0.1 and fold change of ≤0.67 or ≥1.5 
requirements) are listed with their fold change values in Table 2 . The 
list of commonly regulated genes includes 12 genes: ﬁve downreg- 
ulated genes, such as Tgfbr1 (transforming growth factor- β receptor 
I; Fig. 2 A), and seven upregulated genes, such as Stx1a (syntaxin 1A; 
Fig. 2 B). The results were validated using quantitative reverse tran- 
scription polymerase chain reaction (qRT-PCR) and shown as mRNA 
expression ratio to β-actin ( Fig. 2 ) and Gapdh ( Supplementary Fig. 
S5 ). 
3.4. Genes with altered exon splicing regulated by both TDP-43 and FUS 
After ﬁltering the exons in genes that were differentially expressed 
in both shTDP1- and shTDP2-treated neurons, using the threshold of 
a t -test p -value of ≤0.1 and a fold change of ≥1.3 in primary neurons, 
we compared these exons with the proﬁles of alternatively spliced 
exons in shFUS1 and shFUS2 to obtain genes with altered splicing 
events that were commonly regulated by both TDP-43 and FUS. After 
validation by RT-PCR, we obtained 8 exons with alternative splicing 
events regulated by both TDP-43 and FUS ( Table 3 and Fig. 3 ). 
4. Discussion 
Both TDP-43 and FUS are involved in multiple levels of RNA pro- 
cessing, and mutations in these two genes are responsible for familial 
ALS and FTLD. Although TDP-43 and FUS pathologies appear to largely 
be mutually exclusive, the molecular and functional similarities be- 
tween these two molecules suggest that TDP-43 and FUS may share 
a common downstream pathway leading to neuronal degeneration 
[ 29 , 30 ]. 
Genes with altered expression levels or alternatively spliced ex- 
ons in both TDP-43- and FUS-silenced primary neurons have funda- 
mental functions in neurons, suggesting that transcriptome changes 
produced by loss-of-function mutations of TDP-43 and / or FUS may 
lead to neuronal cell death. This conjecture is supported by cross- 
rescue ﬁndings from ﬁsh and ﬂy models in which FUS overexpression 
rescued the defect phenotype caused by TDP-43 knockout [ 20 , 21 ]. 
How do TDP-43 and FUS regulate common downstream genes 
and exons? These proteins do not appear to share the same binding 
target RNAs in neuronal tissue; in particular, it has been reported 
that the consensus sequences of TDP-43 are (UG) repeats [ 31 , 32 ], 
whereas FUS has a widespread RNA binding pattern [ 26 , 33 ]. Research 
has indicated that these two RNA binding proteins may target distinct 
sets of cytoplasmic mRNA molecules in NSC-34 cells [ 34 ]. Although 
we found that there was an overlap of approximately 10% between 
genes with altered splicing after shFUS treatment and genes with 
altered splicing after shTDP-43 treatment, the regulation mechanism 
of common alternative splicing events remains unclear. 
Our results indicated that 25% of genes with altered gene expres- 
sion levels and 10% of genes with alternatively spliced exons were 
common to the transcriptome proﬁles of both TDP-43-silenced pri- 
mary cortical neurons and FUS-silenced primary cortical neurons. 
These ﬁndings were comparable to the results reported by Lagier- 
Tourenne et al., which demonstrated that in adult mouse striatum, 
there was an overlap of more than 10% between alternative splicing 
events observed due to TDP-43 knockdown and alternative splicing 
events observed due to FUS knockdown [ 35 ]. Discrepancies between 
this prior study and the current investigation with respect to targeted 
RNAs could reﬂect the different cell types used in these studies; we 
speciﬁcally assessed neurons, whereas the mouse striatum contains 
a variety of cells, including neurons, glial cells, and other cell types. 
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 In fact, in a recent study, we found distinct FUS-regulated transcrip-
tomes among different cell lineages [ 24 ]. 
Among the target RNA molecules that we identiﬁed, Stx1A is one
of the most differentially upregulated genes in both TDP-43-silenced
neurons and FUS-silenced neurons ( Table 2 ). Stx1A encodes Syntaxin
1A, which is a member of the syntaxin super family that is associated
with the vesicle fusion process as a component of the SNARE complex
[ 36 ]. The overexpression of Stx1A disturbed synaptic vesicle exocy-
tosis in hippocampal neurons [ 37 ], suggesting that up-regulation of
Stx1A by silencing TDP-43 or FUS may produce synaptic dysfunction.
Tgfbr1 is one of the most signiﬁcantly downregulated genes in both
TDP-43-silenced neurons and FUS-silenced neurons ( Table 2 ). Tgfbr1
encodes transforming growth factor (TGF)- β receptor I, which binds
to TGF- β and transduces TGF- β signals from the cell surface to the
cytoplasm. TGF- β signaling was disrupted in the motor neurons of
mouse models of ALS and spinal and bulbar muscular atrophy (SBMA)
[ 38 , 39 ]. This ﬁnding, in combination with our results, suggests that
the TGF- β signaling pathway may be a strong candidate for targeted
molecular therapy for motor neuron degeneration. 
In addition, exon 14 of the Camk2a gene, which encodes the
calcium / calmodulin-dependent protein kinase type II α chain, was
skipped in both TDP-43-silenced primary neurons and FUS-silenced
primary neurons. Camk2a is a critical player in calmodulin-dependent
activity, long-term potentiation (LTP), and learning [ 40 ]. The expres-
sion of Camk2a has been reported to be decreased in Alzheimer’s
patients [ 41 ]. Clarifying the role of exon 14 of Camk2a in the function
of this protein might link the calmodulin-dependent pathway to TDP-
43- and FUS-associated FTLD. Despite the discovery of considerable
evidence linking alternative splicing and various diseases, including
neurodegeneration, it remains unclear how much alternative splic-
ing is “noise” and how much of this splicing truly contributes to cell
fate [ 42 ]. Further veriﬁcation of whether these altered splicing events
have pathogenic roles is required. 
In this study, we determined that TDP-43-silenced neurons and
FUS-silenced neurons exhibited greater overlap in shared gene ex-
pression alterations than in altered splicing events. In addition, a
considerable number of GO terms from gene expression data were
common to both types of neurons, whereas distinct GO terms were
obtained from alternative splicing events in the two types of neurons.
These results suggest that TDP-43 and FUS do not share many splic-
ing targets but instead may associate with each other during mRNA
maturation and / or transportation, resulting in altered gene expres-
sion. Another possibility is that TDP-43 and FUS may share common
molecular pathways that lead to neuronal cell death after multiple
transcriptome disturbances. 
In summary, the comparative analysis of the transcriptome pro-
ﬁles in primary cortical neurons revealed common downstream RNA
targets of TDP-43 and FUS. These targets may be linked to a common
pathway in the neurodegenerative processes of ALS / FTLD. 
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